Lower Respiratory Infections Impose Heavy Costs in Southern Sri Lanka
Hospitalized lower respiratory tract infections impose a substantial economic burden on patients and the public health system in southern Sri Lanka, with each illness episode reaching a median total cost of 125.25 United States dollars despite the nation’s system of free public healthcare. A prospective cohort study tracking 1,268 hospitalized patients revealed that direct medical and non-medical expenses combined with productivity losses create significant household expenditure across the full course of respiratory illness.
Lower respiratory tract infections represent the fourth leading cause of mortality worldwide, and national health data indicate they were the third and fourth leading causes of hospital deaths and overall hospitalizations in Sri Lanka during 2022 and 2023. Although the country’s public healthcare sector provides medical services without user fees, patients frequently encounter indirect financial hurdles and out-of-pocket expenditures. Prior to this investigation, researchers had not quantified the comprehensive episode-level economic burden generated by these respiratory infections within Sri Lanka.
To assess the financial impact from a broad societal perspective, the research team enrolled 1,268 patients admitted with lower respiratory tract infections to a public tertiary care hospital located in Galle, Sri Lanka. Patient enrollment took place over a three-year window extending from April 2018 through March 2021. The enrolled patient cohort presented with a median age of 58.0 years, with an interquartile range spanning from 32.0 to 69.0 years, reflecting substantial representation across both adult and older demographic groups.
The study protocol evaluated costs across three distinct phases of illness: the pre-hospitalization period covering prior care related to the infection, the acute inpatient stay, and the post-hospitalization period extending approximately four weeks after initial admission. Investigators administered standardized questionnaires at baseline enrollment and at a follow-up interview roughly four weeks post-admission. These assessments recorded direct out-of-pocket spending on clinical consultations, prescription medications, diagnostic laboratory tests, and transportation, alongside indirect costs calculated from lost productivity due to missed work or school days.
Direct institutional healthcare delivery expenses were estimated using Sri Lanka-specific models from the World Health Organization Choosing Interventions that are Cost-Effective framework and incorporated into direct cost calculations. All monetary figures were inflation-adjusted to 2020 Sri Lankan Rupees and subsequently converted into 2020 United States Dollars. Across the entire prospective cohort of 1,268 hospitalized individuals, aggregate direct and indirect costs totaled 233,486 dollars.
When broken down by cost category, the median direct cost per hospitalized patient episode was 106.15 dollars, whereas median indirect productivity costs stood at 18.47 dollars. In relation to broader household financial standing, the median per-patient cost consumed 13.2 percent of annual per-capita household income. Subgroup evaluations further identified notable age-specific differences, showing that children between the ages of 6 and 10 years incurred the highest median total economic cost among all evaluated age segments.
Prior to being admitted to the tertiary facility, 69.6 percent of participants had already sought outpatient care for their illness, and 23.2 percent required additional healthcare consultations following discharge. Inpatients recorded a median hospital length of stay of four days, with an interquartile range of three to five days, and 95.7 percent of the cohort received antibiotic therapy during admission.
The researchers noted that these baseline cost evaluations provide vital economic evidence to support health technology assessment in Sri Lanka. Quantifying the financial drain imposed by acute lower respiratory illness helps clarify the value proposition of preventive public health interventions, such as immunization programs and targeted vaccines designed to reduce the incidence and clinical severity of lower respiratory tract pathogens.
Subject of Research: Economic burden of hospitalized lower respiratory tract infections in Sri Lanka
Article Title: Economic costs of lower respiratory tract infections among hospitalized patients in southern Sri Lanka: a prospective cohort study
Article References: Ulak, H., Neighbors, C. E., Kurukulasooriya, R., Vanderburg, S., Wijayaratne, G. B., Weerasinghe, N. P., Bodinayake, C. K., Nagahawatte, A. D. S., Obale, A., Østbye, T., Woods, C. W., & Tillekeratne, L. G. (2026). Economic costs of lower respiratory tract infections among hospitalized patients in southern Sri Lanka: a prospective cohort study. Health Economics Review . https://doi.org/10.1186/s13561-026-00848-3
Keywords: Lower respiratory tract infections, Sri Lanka, Galle, Health economics, Hospitalization costs, Out-of-pocket costs, Direct medical costs, Indirect costs, Productivity loss, Prospective cohort study, Public healthcare system, WHO-CHOICE, Antibiotic use, Length of stay, Pediatric respiratory infections, Health technology assessment, Vaccine economic evaluation
News Source: Ophelia Keating. (November 20, 2026). Lower Respiratory Infections Impose Heavy Costs in Southern Sri Lanka. Scienmag.
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Enter your email address to subscribe to this blog and receive notifications of new posts by email.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Please enter your username or email address to reset your password.
Loading comments…